ALPMY:OTC-Astellas Pharma Inc (USD)

COMMON STOCK | Drug Manufacturers—General | OTC

Last Closing Price

USD 15.24

Change

-0.21 (-1.36)%

Market Cap

USD 28.68B

Volume

0.06M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-21 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHBF Roche Holding AG

-3.10 (-0.82%)

USD323.96B 22.46 15.16
RHHVF Roche Holding AG

-6.91 (-1.85%)

USD319.14B 22.48 15.16
RHHBY Roche Holding AG

-0.54 (-1.15%)

USD316.59B 22.54 15.16
NVSEF Novartis AG

+0.20 (+0.22%)

USD204.44B 29.19 14.35
AZNCF AstraZeneca PLC

-0.96 (-0.85%)

USD146.98B 68.03 20.40
SNYNF Sanofi

-0.33 (-0.32%)

USD130.27B 9.94 7.89
GLAXF GlaxoSmithKline plc

+0.14 (+0.72%)

USD95.84B 11.57 14.25
CHGCF Chugai Pharmaceutical Co., Ltd

N/A

USD75.10B 42.07 0.29
CHGCY Chugai Pharmaceutical Co., Ltd

-0.19 (-0.85%)

USD73.17B 41.97 0.29
BAYZF Bayer Aktiengesellschaft

-3.68 (-5.44%)

USD66.87B 22.76 10.06

ETFs Containing ALPMY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.51% 34% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.51% 34% F 47% F
Trailing 12 Months  
Capital Gain 7.55% 49% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.55% 46% F 62% D-
Trailing 5 Years  
Capital Gain 12.56% 43% F 59% F
Dividend Return 3.19% 32% F 17% F
Total Return 15.75% 37% F 55% F
Average Annual (5 Year Horizon)  
Capital Gain 4.43% N/A N/A N/A N/A
Dividend Return 0.41% N/A N/A N/A N/A
Total Return 4.84% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.68% N/A N/A N/A N/A
Risk Adjusted Return 30.84% N/A N/A N/A N/A
Market Capitalization 28.68B 61% D- 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.17 85% B 46% F
Price/Book Ratio 2.30 63% D 39% F
Price / Cash Flow Ratio 0.13 81% B- 44% F
EV/EBITDA 0.09 83% B 79% C+
Management Effectiveness  
Return on Equity 14.65% 66% D 85% B
Return on Invested Capital 15.36% 72% C- 78% C+
Return on Assets 7.49% 66% D 92% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.73 25% F 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:

There is nothing we particularly dislike